Evidence map›Paper›PMID 35338209›Full record

ArticleScientific reports2022

Microwell bag culture for large-scale production of homogeneous islet-like clusters.

Ryo Suenaga, Shuhei Konagaya, Junji Yamaura, Ryo Ito, Satoshi Tanaka, Yoichi Ishizaki, Taro Toyoda

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ryo Suenaga *Corporate Research & Development, Toyo Seikan Group Holdings, Ltd., Yokohama, Japan. ryou_suenaga@tskg-hd.com.
Shuhei Konagaya *iPSC-derived Pancreatic Islet Cells (iPIC) Therapy Department, Orizuru Therapeutics, Inc., Fujisawa, Kanagawa, Japan.
Junji YamauraCell Therapies, Pharmaceutical Science, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.
Ryo ItoiPSC-derived Pancreatic Islet Cells (iPIC) Therapy Department, Orizuru Therapeutics, Inc., Fujisawa, Kanagawa, Japan.
Satoshi TanakaCorporate Research & Development, Toyo Seikan Group Holdings, Ltd., Yokohama, Japan.
Yoichi IshizakiCorporate Research & Development, Toyo Seikan Group Holdings, Ltd., Yokohama, Japan.
Taro ToyodaDepartment of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan. t.toyoda@cira.kyoto-u.ac.jp.
Toyo Seikan (Japan) · JPKyoto University · JPTakeda (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pluripotent stem-cell derived cells can be used for type I diabetes treatment, but we require at least 10

Indexed as

Diabetes Mellitus, Type 1Induced Pluripotent Stem CellsPluripotent Stem CellsCell DifferentiationHumans

Identifiers

PMID35338209
PMCPMC8956638
OpenAlexW4220885611

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.